Wells Fargo Thinks Charles River Labs’ Stock is Going to Recover

Wells Fargo analyst Timothy Daley maintained a Buy rating on Charles River Labs (CRLResearch Report) today and set a price target of $325.00. The company’s shares closed last Monday at $252.64, close to its 52-week low of $251.30.

According to, Daley is a 2-star analyst with an average return of 0.3% and a 50.0% success rate. Daley covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, Stevanato Group, and Mettler-Toledo.

Charles River Labs has an analyst consensus of Strong Buy, with a price target consensus of $372.30, which is a 44.8% upside from current levels. In a report issued on April 18, Robert W. Baird also maintained a Buy rating on the stock with a $351.00 price target.

See the top stocks recommended by analysts >>

Charles River Labs’ market cap is currently $13.87B and has a P/E ratio of 35.91.

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRL in relation to earlier this year. Last month, Smith David Ross, the Corporate Executive VP & CFO of CRL sold 8,965 shares for a total of $2,532,889.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client’s use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Read More on CRL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More